Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALK-N001 in Advanced Solid Tumors
NCT07509684Phase 2Not yet recruiting
- Sponsor
- Zhejiang Anglikang Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
A Phase 2 trial of QHL-1618 in solid tumor (advanced stage), sponsored by Zhejiang Anglikang Pharmaceutical. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
QHL-1618
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07509684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509684.